世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000034100

末梢神経鞘腫(神経線維肉腫)の治療薬開発市場:ステージ別、標的別、作用機序別、投与経路別、分子タイプ別、主要企業別(2022年度版)

Global Markets Direct

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

発刊日 2022/12/28

言語英語

体裁PDF/82ページ

ライセンス/価格82ページ

0000034100

Single
Site
Enterprisewide (Global Site)

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

本レポートは、末梢神経鞘腫(神経線維肉腫)(腫瘍学)のパイプラインの概要を提供します。

悪性末梢神経鞘腫瘍(MPNST)は、末梢神経または神経鞘に関連する細胞(シュワン細胞、神経周囲細胞、線維芽細胞など)から発生する肉腫です。症状としては、軟部組織のしこりや腫れ、しびれ、焼け付くような痛み、針が刺さったような感覚、患部の筋力低下、めまいや平衡感覚喪失などがあります。治療には、手術、放射線治療、化学療法があります。

注:パイプラインガイドの一部のコンテンツ/セクションは、データの入手可能性と関連性に基づいて削除または変更される場合があります。

調査範囲

  • 末梢神経鞘腫(神経線維肉腫)治療薬(腫瘍学)の世界的な治療状況についてのスナップショットを提供します。
  • 企業や業界固有の情報源から得た情報に基づいて、企業や大学・研究機関が開発中の末梢神経鞘腫(神経線維肉腫)治療薬のパイプラインをレビューしています。
  • 登録前から創薬、未公開段階までの様々な開発段階のパイプライン製品をカバーしています。
  • 本レポートでは、パイプライン製品について、製品の説明、ライセンスおよび共同研究の詳細、研究開発の概要、作用機序(MoA)やその他の開発活動を含む、治療薬プロファイルを提供します。
  • 末梢神経鞘腫(神経線維肉腫)治療薬に関わる主要企業をレビューし、その主要および小規模プロジェクトをすべて掲載します。
  • 作用機序(MoA)、薬物標的、投与経路(RoA)、および分子タイプに基づいて、末梢神経鞘腫(神経線維肉腫)治療薬を評価します。
  • すべての休止中および中止されたパイプラインプロジェクトを要約します。
  • 末梢神経鞘腫(神経線維肉腫)を標的としたパイプライン治療薬に関連する最新のニュースをレビューします。

レポート詳細

目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
3SBio Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Eisai Co Ltd
Epizyme Inc
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Mirati Therapeutics Inc
Moleculin Biotech Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Tango Therapeutics Inc
Vyriad Inc
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
(cedazuridine + decitabine) - Drug Profile
Product Description
Mechanism Of Action
afamitresgene autoleucel - Drug Profile
Product Description
Mechanism Of Action
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
Annamycin - Drug Profile
Product Description
Mechanism Of Action
APG-115 - Drug Profile
Product Description
Mechanism Of Action
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
axitinib - Drug Profile
Product Description
Mechanism Of Action
camrelizumab - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
ecubectedin - Drug Profile
Product Description
Mechanism Of Action
eribulin mesylate - Drug Profile
Product Description
Mechanism Of Action
everolimus - Drug Profile
Product Description
Mechanism Of Action
ganetespib - Drug Profile
Product Description
Mechanism Of Action
HSV-1716 - Drug Profile
Product Description
Mechanism Of Action
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
MRTX-9768 - Drug Profile
Product Description
Mechanism Of Action
OMTX-703 - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
pamiparib - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
pexidartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
selinexor - Drug Profile
Product Description
Mechanism Of Action
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
sitravatinib malate - Drug Profile
Product Description
Mechanism Of Action
SSGJ-609A - Drug Profile
Product Description
Mechanism Of Action
tazemetostat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
telaglenastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
TNG-908 - Drug Profile
Product Description
Mechanism Of Action
TQB-3234 - Drug Profile
Product Description
Mechanism Of Action
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by 3SBio Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Adaptimmune Therapeutics Plc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Advenchen Laboratories LLC, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Ascentage Pharma Group International, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bristol-Myers Squibb Co, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Eisai Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Karyopharm Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Mirati Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Moleculin Biotech Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatryx Biopharma SL, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics LLC, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pharma Mar SA, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sino Biopharmaceutical Ltd, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Tango Therapeutics Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, 2022
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

この商品のレポートナンバー

0000034100

TOP